Programa DEFINITIVO
DESCARGAR PROGRAMA DEFINITIVO Programa
 
 
HORARIO DEL REGISTRO DURANTE EL CONGRESO:
Domingo 5 de Junio, de 12.00 h. a 18.00 h.
Lunes 6 de Junio, de 9 h. a 13.30 h. y de 15.00 h. a 18.30 h.
Martes 7 de Junio, de 9 h. a 13.30 h. y de 15.00 h. a 18.30 h.
Miércoles 8 de Junio, de 9 h. a 13.30 h.
DESCARGAR DISTRIBUCIÓN DE POSTERS Programa
 
  Plenary Speakers   Key-notes speakers  
 
   
 
 

PLENARY SPEAKERS

  Dr. Pedro J. Álvarez

Dr. Pedro J. J. Alvarez is the George R. Brown Professor of Engineering and the chair of the Department of Civil and Environmental Engineering at Rice University. He previously taught at the University of Iowa, where he also served as Associate Director for the Center for Biocatalysis and Bioprocessing and as Honorary Consul for Nicaragua. Dr. Alvarez received the B. Eng. Degree in Civil Engineering from McGill University and MS and Ph.D. degrees in Environmental Engineering from the University of Michigan.

Prof. Alvarez's research focuses on environmental sustainability through bioremediation of contaminated aquifers, fate and transport of toxic chemicals, water footprint of biofuels, microbial-plant interactions, water treatment and reuse, and environmental implications and applications of nanotechnology.

Dr. Alvarez is the 2012 Clarke Prize Recipient and also won the 2014 AAEES Grand Prize for Excellence in Environmental Engineering and Science. He is a Diplomat of the American Academy of Environmental Engineers, a Fellow of AAAS, ASCE, IWA, WEF and the Leopold Leadership Foundation, and a founding member of the Nicaraguan Academy of Sciences.

Past honors include President of AEESP, the Malcolm Pirnie-AEESP Frontiers in Research Award, the WEF McKee Medal for Groundwater Protection, the SERDP cleanup project of the year award, the Button of the City of Valencia, the Collegiate Excellence in Teaching Award from the University of Iowa; the Alejo Zuloaga Medal from the Universidad de Carabobo, Venezuela; a Career Award from the National Science Foundation; a Rackham Fellowship, and various best paper awards with his students.

Dr. Alvarez currently serves as Associate Editor of Environmental Science and Technology. Additionally, he serves as honorary professor at Nankai University in Tianjin and the Chinese Academy of Sciences in Beijing, China, and as adjunct professor at the Universidade Federal de Santa Catarina in Florianopolis, Brazil and recently completed service on the EPA's Science Advisory Board.

Convergence of Nanotechnology and Microbiology: Environmental Applications and Implications | Miércoles día 8 | 17 h.

  Dr. Tejal Desai

Dr. Tejal Desai is currently Professor and Chair of the Department of Bioengineering and Therapeutic Sciences at the University of California, San Francisco. She is a member of the California Institute for Quantitative Biomedical Research, PI of the UCSF/UC Berkeley Graduate Group NIH Training Grant in Bioengineering, and founding faculty director of the UCSF/UC Berkeley Master's in Translational Medicine. Prior to joining UCSF, she was an Associate Professor of Biomedical Engineering at Boston University and Associate Director of the Center for Nanoscience and Nanobiotechnology at BU. She received the Sc.B. degree in Biomedical Engineering from Brown University in 1994 and the Ph.D. degree in bioengineering from the joint graduate program at University of California, Berkeley and the University of California, San Francisco, in 1998.

Dr. Desai currently directs the Laboratory of Therapeutic Micro and Nanotechnology where her research brings together advanced micro and nanotechnologies, fundamental insight into cellular behavior in engineered environments, and novel pharmacologic delivery approaches to address disease treatment and clinical translation. Currently, her laboratory focuses on four highly interdisciplinary directions: 1. Hierarchical devices for enhanced cellular adhesion and paracellular drug transport; 2. Injectable and flexible nanoporous devices for rate-controlled long term release of therapeutics; 3. Nanostructured coatings and scaffolds for pro-healing implants and in vivo modulation of fibrosis, and 4. Cell-based delivery platforms for autoimmune disease applications. By taking advantage of an understanding of how cells respond to engineered materials and the ability to fabricate precise structural domains, her lab seeks to design new platforms to overcome existing challenges in therapeutic delivery.

In addition to authoring over 170 peer-reviewed papers and delivering over 200 invited talks, she is presently a senior editor of Langmuir and Biomedical Microdevices, and co-editor of an encyclopedia on Therapeutic Microtechnology. Dr. Desai has chaired and organized numerous conferences and symposia in the area of biomedical micro and nanotechnology, drug delivery and tissue engineering, and serves as Chair of the NIH Biomaterials and Biointerfaces study section. She also sits on the steering committee of the Whitaker Foundation and is on the external advisory committees of several bioengineering departments nationally. Her other interests include K-12 educational outreach, gender and science education, science policy issues, and bioengineering industry outreach.

Her research efforts have earned national and international recognition including Technology Review's "Top 100 Young Innovators," Popular Science's Brilliant 10, and NSF's "New Century Scholar". She also received the Eurand Grand Prize and Pfizer/Capsugel Awards for innovative drug delivery technology, the Young Career Award from the Engineering in Medicine and Biology Society (IEEE EMBS), and the UC Berkeley Distinguished Young Alumni award. More recently she received the Dawson Biotechnology Award and was elected as a fellow of both AIMBE and BMES.

Nanostructured Interfaces for Enhanced Therapeutic Delivery | Domingo día 5 | 18 h.

  Dr. Juan José Estruch Miñana

Dr. Juan José Estruch studied Biology at University of Valencia and his PhD was carried out between IBMCP-CSIC and University of Essen (Germany). After that, he had his post-doctoral stays in Max-Planck Institute (Colonia, Germany). Furthermore, he has Master studies in Economics (Fuqua School of Business, University of Duke, USA).

He was Director for Business and Licenses in Novartis (an international factory for pharmaceuticals and other products). After that, he was Vice-president in Diversa (platform for production of different antibodies and enzymes for different uses). Finally, he was Director for oncology diagnosis in Prometheus (international company specialized in products/pharmaceuticals for diagnosis in gastric pathologies and oncology).

Actually, he is Director in Y-On-Health (holding company for investment in private companies), General Director in Vet-therapeutics Inc (company for antibodies development to pets), and General Director in Vetical-Labs Inc (leader company in veterinary diagnosis products).

Una Trayectoria Personal En La Formacion y Desarrollo de Companias Basadas en Ciencia y Tecnologia | Martes día 7 | 15 h.

  Dr. Paulo Mazzafera

He is Agriculture Engineering at High Agriculture School Luiz de Queiroz (1982), Msc in Biological Sciences (1987), and PhD in Biological Sciences (1990). In 2000 was incorporated as Associate Proffesor and in 2001 as Full Professor in the State University of Campinas. He had some post-PhD stays, one of them at Sweden University in Umeä, and the other one in CSIRO, Adelaida, Australia (Commowealth Scientific International Research Organization). Nowadays, his research topics are related with secondary metabolism of coffee, eucalyptus and sugar cane. Also, he is now director of CBTE, Brazilian Laboratory of Bioethanol Science and Technology.

An overview of second generation bioethanol in Brazil | Miércoles día 8 | 9 h.

  Dr. Martin Schurmann

Prof. Schurmann is actually principal Scientist Biocatalysis at DSM Engineering Plastics in Geleen (Netherlands). He developed his PhD (1998-2001) in C-C bond forming enzymes, in the Institute of Biotechnology I (Research Center Jülich). Later, he continued his Post-Doc work at the same center during 2001 and 2002 (studying Proteomics techniques for metabolic pathway engineering of aromatics in Escherichia coli). After that, he joined DSM Pharmaceutical Products in Geleen. Prof. Schurmann is co-author of more than 40 peer-reviewed scientific articles, book chapters and international patents. Nowadays, he is the coordinator of the EU Horizon 2020 Innovation action ROBOX on robust bioixidations.

Mild and selective biocatalytic hydroxy-functionalization using hydratases and monooxygenases for the industrial production of chiral and functional chemicals | Martes día 7 | 9 h.

  Mark Sliwkowski, Ph.D.

Mark is a Distinguished Staff Scientist in Molecular Oncology at Genentech, Inc. He received his B.S. from the University of Delaware and his Ph.D. in biochemistry with a minor in physical chemistry from North Carolina State University. Mark was a postdoctoral fellow in the laboratory of Dr. Theresa C. Stadtman in the Laboratory of Biochemistry, in the National Heart, Lung, and Blood Institute at NIH. Upon leaving NIH, he joined Triton Biosciences, Inc., where he studied growth factor receptors and their ligands. Mark joined Genentech in 1991 and worked on a number of programs involving drugs directed against the human epidermal growth factor receptor family (also known as the HER or ErbB family). Dr. Sliwkowski was involved in the research and development efforts for Herceptin® (trastuzumab) and Tarceva® (erlotinib). Two drugs which arose from his laboratory’s research, Perjeta® (pertuzumab) and Kadcyla® (ado-trastuzumab emtansine) have received regulatory approval for the treatment of HER2-positive breast cancer. Dr. Sliwkowski is an inventor on over 30 issued patents and has authored more than 100 scientific publications.

Targeting Activated HER2/ErbB2 in Solid Tumors | Lunes día 6 | 9 h.

  Dr. Roberto Solano

Roberto Solano is Research Teacher of CSIC (Spain), in National Center for Biotechnology (CNB-MADRID). Solano finished his PhD in 1995 in the University of Alcala de Henares. At the same university, he obtained previously his BsC in Biology. From that moment, he works in molecular mechanisms for jasmonic acid signaling in plants. The contributions of his research group have clarified numerous doubts related with receptors and transcription factors in that signaling pathway. He was the first to use microarrays DNA from Arabidopsis thaliana, thanks to European projects CATMA and CAGE. His scientific excellence causes several publications in journals of high impact, and invited lectures in many international and national Congress. Furthermore, he was designed by Thomson and Reuters as one of the most cited authors in the Area of Plant and Animal Science, in 2014 and 2015.

Biology and Biotechnology of Jasmonates | Lunes día 6 | 15 h.

 
 
Siguenos en Twitter
   
Siguenos en Facebook
Clima en Salamanca